chufangao/CTO huggingface dataset:
Clinical trial NCT04899271: A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes and Preserved Beta-cell Function at Baseline.
Sponsor: Dompé Farmaceutici S.p.A (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: low recruitment rate
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-14
Primary completion date: 2023-04-27
Completion date: 2023-10-11
Plan to share individual participant data: NO
Clinical trial NCT03982004: Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
Official title: Phase IB Pilot Study of Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-14
Primary completion date: 2021-03-03
Completion date: 2021-03-03
Plan to share individual participant data: NO
Clinical trial NCT04020601: The Impact of a Preoperative Nerve Block on the Consumption of Sevoflurane in Total Shoulder Arthroplasty
Official title: The Impact of a Preoperative Nerve Block on the Consumption of Sevoflurane in Total Shoulder Arthroplasty
Sponsor: University of Alberta (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: COVID-19 Pandemic
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-01
Primary completion date: 2020-03-15
Completion date: 2020-03-15
Clinical trial NCT03317795: Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids
Official title: Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-14
Primary completion date: 2020-12-28
Completion date: 2020-12-28
Clinical trial NCT04249427: Erenumab for Idiosyncratic Facial Pain
Official title: A Randomized, Double-Blinded, Single Site Study to Evaluate the Efficacy of Erenumab for Treatment of Idiosyncratic Facial Pain Mimicking Rhinosinusitis
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 29.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-10
Primary completion date: 2023-07-11
Completion date: 2023-07-11
Plan to share individual participant data: NO
Clinical trial NCT04688775: Eptinezumab in Participants With Episodic Cluster Headache
Official title: Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache
Acronym: ALLEVIATE
Sponsor: H. Lundbeck A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 231.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-23
Primary completion date: 2023-06-14
Completion date: 2023-10-05
Baseline population: The all-participants-randomized-set (APRS) included all randomized participants. The all-participants-treated set (APTS) included all randomized participants who received infusion with double-blind investigational medicinal product (IMP). Demographic characteristics were collected for the APTS and study-specific characteristics were collected for the APRS.
Clinical trial NCT03785925: A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
Official title: A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients
Acronym: PIVOT-10
Sponsor: Nektar Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 192.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-29
Primary completion date: 2022-02-09
Completion date: 2022-06-30
Baseline population: The analysis population consisted of 188 patients.
Plan to share individual participant data: NO
Clinical trial NCT02769611: Ruboxistaurin in New York Heart Failure Classification III-IV Patients
Official title: A Prospective Phase I/II Dose Escalation Pilot Analysis of Ruboxistaurin (LY333531) for Safety in New York Heart Failure Classification III-IV Patients, As Well As For Efficacy in Acutely Augmenting Cardiac Function.
Sponsor: University of Tennessee (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: No funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-06-28
Primary completion date: 2022-01-01
Completion date: 2022-01-01
Plan to share individual participant data: NO
Clinical trial NCT03260504: Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Official title: A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Insufficient funding
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-28
Primary completion date: 2022-07-26
Completion date: 2022-07-26
Plan to share individual participant data: NO
Clinical trial NCT04346446: Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients
Official title: Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial
Sponsor: Institute of Liver and Biliary Sciences, India (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 29.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-20
Primary completion date: 2020-05-30
Completion date: 2020-05-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05908396: Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
Official title: An Open-Label, Multicenter, Phase 1 Study of IGM-2644 in Participants With Relapsed and/or Refractory Multiple Myeloma
Sponsor: IGM Biosciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Company Decision
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-08-29
Primary completion date: 2024-02-16
Completion date: 2024-02-16
Clinical trial NCT04105985: Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics
Official title: Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth: A Randomized Clinical Trial
Sponsor: Virginia Commonwealth University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Manufacturer discontinued drug before any participants could be enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-31
Primary completion date: 2021-08-31
Completion date: 2021-08-31
Plan to share individual participant data: NO
Clinical trial NCT02178436: Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
Official title: Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer
Sponsor: Barbara Ann Karmanos Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 15.0 (ACTUAL)
Number of arms: 3.0
Start date: 2014-10-31
Primary completion date: 2021-11-27
Completion date: 2023-04-05
Baseline population: Group II enrolled no patients because patients refused to undergo the required biopsy.
Clinical trial NCT02765243: Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
Official title: Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells (4SCAR-GD2) Targeting Refractory and/or Recurrent Neuroblastoma
Acronym: 4SCAR-GD2
Sponsor: Zhujiang Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-01-01
Primary completion date: 2019-01-12
Completion date: 2023-12-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03524274: Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer
Official title: Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Colorectal Cancer
Sponsor: Fuda Cancer Hospital, Guangzhou (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-04-05
Primary completion date: 2020-05-20
Completion date: 2020-08-05
Clinical trial NCT03760523: Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
Official title: Phase 1/1b Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
Sponsor: H. Lee Moffitt Cancer Center and Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Toxicity -Two DLT events occurred
Enrollment: 27.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-18
Primary completion date: 2023-10-09
Completion date: 2023-10-09
Clinical trial NCT03724357: Blood Donor CVD 9000
Official title: Blood Donor CVD 9000: Collection of Blood for In Vitro Studies From Healthy Adults Who Have Received Oral Cholera Vaccine (CVD 103-HgR)
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: lack of funding
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-04
Primary completion date: 2021-10-28
Completion date: 2021-10-28
Plan to share individual participant data: NO
Clinical trial NCT04003142: A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2
Official title: A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause
Acronym: Skylight 2
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 501.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-07-10
Primary completion date: 2020-07-30
Completion date: 2021-04-23
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Clinical trial NCT02636582: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
Official title: VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 43.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-14
Primary completion date: 2019-07-22
Completion date: 2023-05-17
Baseline population: Randomized participants.
Clinical trial NCT04378569: Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
Official title: A Phase 1/2b, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects With Chronic Hand Eczema
Sponsor: Arcutis Biotherapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 230.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-04-20
Primary completion date: 2021-02-24
Completion date: 2021-02-24
Plan to share individual participant data: NO
Clinical trial NCT03935217: A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis
Official title: Multi-center, Prospective, Randomized, Placebo-Controlled, Delayed Treatment, Double-Blind Study to Evaluate the Effectiveness and Safety of a Single Oral Dose of Solosec® for the Treatment of Trichomoniasis
Sponsor: Lupin Research Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 147.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-23
Primary completion date: 2020-03-02
Completion date: 2020-03-25
Baseline population: Safety Population
Plan to share individual participant data: YES
IPD sharing description: All IPD that underlie results in a publication
IPD time frame: After publication of the primary study results, the research team will prepare final research data files that may be shared with other investigators, upon request.
IPD access criteria: Requests for research data must be submitted to author CAM in writing, via a standard data request form, with a justification for how the data will be used. Author CAM and Lupin Pharmaceuticals will review all requests for research data obtained from this study. The mechanism by which the data will be made available to investigators will follow all NIH guidelines for data sharing as they evolve. At a minimum this would consist of a data use agreement that provides for commitments to use the data for research purposes only, secure the data with appropriate computer technology, obtain IRB approval, and destroy (or return) the data after analyses are complete.
Clinical trial NCT04687800: Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery
Official title: A Randomized, Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Conjunction With Cataract Surgery Performed in Combination With Minimally Invasive Glaucoma Surgery
Sponsor: The Eye Associates (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Inability to enroll due to lack of access to the Ambulatory Surgery Center.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-01
Primary completion date: 2022-10-24
Completion date: 2022-10-24
Clinical trial NCT02715466: Gelatin in ICU and Sepsis
Official title: Prospective, Controlled, Double-Blind, Randomized Multicentric Study On The Efficacy And Safety Of An Early Target Controlled Plasma Volume Replacement Therapy With A Balanced Gelatine Solution vs A Balanced Electrolyte Solution In Patients With Severe Sepsis
Acronym: GENIUS
Sponsor: B. Braun Melsungen AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: recommended by DSMB
Enrollment: 167.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-04-30
Primary completion date: 2021-12-08
Completion date: 2021-12-08
Clinical trial NCT05137717: A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
Official title: A Phase 3, Open-Label, Single-Arm Study to Assess the Efficacy, Safety, and Pharmacokinetics of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Japanese Recipients of a Hematopoietic Stem Cell Transplant (HSCT) or Solid Organ Transplant (SOT)
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 41.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-01-18
Primary completion date: 2023-06-27
Completion date: 2023-06-27
Baseline population: Full analysis set (FAS) included of all participants who had taken at least 1 dose of study treatment.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT03748134: Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Official title: A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 746.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-12-24
Primary completion date: 2021-09-09
Completion date: 2023-07-29
Plan to share individual participant data: NO
Clinical trial NCT03788694: Intranasal Ketamine for Suicidal Ideation in Veterans
Official title: Pilot Study of Open Label, Intranasal Ketamine for Suicidal Ideation in Veterans
Sponsor: Bronx Veterans Medical Research Foundation, Inc (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Study was never funded nor started, no participants were enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-01
Primary completion date: 2020-01-31
Completion date: 2020-04-30
Plan to share individual participant data: YES
IPD sharing description: All IPD that underlie results in publications as well as study protocol, statistical analysis plan, informed consent form.
IPD time frame: 6 months after publication and will remain available for 5 years.
Clinical trial NCT04818736: COVID-19 Vaccine For Indirect Protection
Official title: COVID Vaccine for Indirect Protection: A Cluster Randomized Controlled Trial in Hutterite Colonies
Sponsor: McMaster University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Vaccine roll out plans increased so timing was no longer feasible
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-15
Primary completion date: 2021-09-30
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT04006691: Efficacy and Safety of UGN-101 in Recurrent Patients
Official title: A Phase 3b Multicenter Extension Trial Evaluating the Efficacy and Safety of UGN-101 (Mitomycin Gel) for Instillation on Ablation of Upper Urinary Tract Urothelial Carcinoma in Recurrent Patients From Trial TC-UT-03
Acronym: Retreatment
Sponsor: UroGen Pharma Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Due to projected low enrollment, it has decided not to move forward with the study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-01
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Plan to share individual participant data: NO
Clinical trial NCT03870334: Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
Official title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
Sponsor: NImmune Biopharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Decision of Landos Biopharma (not related to safety or efficacy)
Enrollment: 27.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-05
Primary completion date: 2022-08-26
Completion date: 2022-08-26
Plan to share individual participant data: NO
Clinical trial NCT03962738: A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine
Official title: RandoMized, DOuble-bliNd, PlacebO-coNtrolled Trial Of Lasmiditan in a Single Migraine Attack in Japanese Patients SuFfering From Migraine With or WithoUt Aura - the MONONOFU Study
Acronym: MONONOFU
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 846.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-05-31
Primary completion date: 2020-06-08
Completion date: 2020-06-08
Baseline population: All participants who received at least one dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03829930: Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer
Official title: A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer
Sponsor: George Washington University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor discontinued the drug
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-01
Primary completion date: 2020-09-01
Completion date: 2020-09-01
Plan to share individual participant data: UNDECIDED